Abstract:Kridsanai Gulapa, Dararat Eksombatchai, Tananchai Petnak, Viboon Boonsarngsuk Division of Pulmonary Medicine and Pulmonary Critical Care Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Correspondence: Dararat Eksombatchai, Division of Pulmonary Medicine and Pulmonary Critical Care Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Bangkok, 10400, Thailand, Email Background: COVID-19 infection is associated with an increased risk of severe illness and adverse outcomes in individuals with immunocompromising conditions. Immunocompromised patients may have difficulty with viral clearance, which can lead to persistent infection and potential relapses in viral replication. Case Presentation: Herein, we present four cases of persistent COVID-19 pneumonia in immunocompromised patients, including those with diffuse large B-cell lymphoma, polyarteritis nodosa, and end-stage renal disease post-kidney transplant. Three patients had previously received rituximab. Notably, all patients in this cohort demonstrated positive anti-receptor binding-domain immunoglobulin G (IgG) and negative anti-nucleocapsid IgG values. Conclusion: Persistent COVID-19 infection should be considered in the differential diagnosis of immunocompromised patients who exhibit ongoing symptoms or lack of improvement in chest X-ray findings following initial COVID-19 treatment. Early recognition, beyond the diagnosis of post-COVID organizing pneumonia, may significantly improve clinical outcomes with timely and appropriate treatment. Keywords: COVID-19 pneumonia, persistent COVID-19, immunocompromised patients, SAR-CoV-2 COVID-19 infection has been associated with an increased risk of hospitalization and mortality in individuals with immunocompromising conditions. 1–3 T cell-depleting drugs and B cell-depleting therapies have been linked to more severe COVID-19 illness. 4 Additionally, these patients may experience relapses in viral replication, delayed viral clearance, and persistent infection. 5,6 We report four cases of persistent COVID-19 pneumonia in immunocompromised patients: two with diffuse large B-cell lymphoma (DLBCL), one with polyarteritis nodosa (PAN), and one with end-stage renal disease (ESRD) post-kidney transplant (KT). Three patients had received rituximab therapy. Notably, all patients within the cohort demonstrated positive anti-receptor binding-domain immunoglobulin G (Anti-RBD IgG) and negative anti-nucleocapsid immunoglobulin G (Anti-N IgG) results. A 36-year-old woman with a 10-year history of PAN complicated by cryoglobulinemia presented in May 2023 with a two-week history of fever, shortness of breath, and cough. She had been on rituximab for the past six years, with the last dose administered six months prior, along with methotrexate (7.5 mg/week) and azathioprine (50 mg/day). She had a documented prior SARS-CoV-2 infection in May 2022. The patient had received the final dose of mRNA-1273 COVID-19 vaccine 15 months before this period ( Supplementary Table 1 ). On presentation, she had a high fever and an oxygen saturation (SpO2) of 94%. Both nasopharyngeal swab (NPS) antigen test kit (ATK) and polymerase chain reaction (PCR) were positive for SARS-CoV-2 with a cycle threshold (Ct) of 18. There was no significant travel history or known household exposure to COVID-19 during this period. She received a 10-day course of remdesivir, methylprednisolone (250 mg), tapering to dexamethasone over 30 days, and two weeks of baricitinib, showing significant improvement post-treatment (Figure 1A–C). Figure 1 ( A-H ) Demonstrating chest radiograph of patient No.1. Despite this, she experienced persistent symptoms and chest X-ray (CXR) abnormalities for five months, diagnosed as post-COVID organizing pneumonia (OP). Initial dexamethasone (8 mg/day) was ineffective. In July 2023, her CXR showed increased opacities, prompting a 5-day course of dexamethasone (10 mg/day). However, adding tofacitinib and reducing corticosteroids did not change her symptoms and CXR findings (Figure 1D–F). A transbronchial biopsy revealed mild chronic inflammation without evidence of other infections. Active Livedo reticularis from August to October 2023 led two doses of rituximab, with slight improvement in her CXR. She received two additional 400 mg doses in October and November 2023, but intermittent cough and bilateral reticular opacities persisted. Worsening dyspnea resulted in hospital admission in November-December 2023. Bronchoalveolar lavage (BAL) revealed SARS-CoV-2 via RT-PCR with a Ct of 25.5. Her serum anti-RBD IgG was 2091.8 AU/mL, while anti-N IgG remained negative. An extended 21-day co -Abstract Truncated-

Persistent COVID-19 Infection in an Immunocompromised Host: A Case Report

Case reports of persistent SARS-CoV-2 infection outline within-host viral evolution in immunocompromised patients

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Persistent COVID-19: A Case Report of an Immunocompromised Patient and a Literature Review

SARS-CoV-2 evolution during prolonged infection in immunocompromised patients

Different Within-Host Viral Evolution Dynamics in Severely Immunosuppressed Cases with Persistent SARS-CoV-2

Persistence of SARS‐CoV‐2 infection and viral intra‐ and inter‐host evolution in COVID‐19 hospitalized patients

Characteristics of virus and antibody response in an immunocompromised patient with persistent SARS-CoV-2 infection

Intrahost evolution leading to distinct lineages in the upper and lower respiratory tracts during SARS-CoV-2 prolonged infection

SARS-CoV-2 variants from long-term, persistently infected immunocompromised patients have altered syncytia formation, temperature-dependent replication, and serum neutralizing antibody escape

Intra-Host Evolution Analyses in an Immunosuppressed Patient Supports SARS-CoV-2 Viral Reservoir Hypothesis

Persistent SARS-CoV-2 infection: significance and implications

Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values

Resilience and Beyond the Acute Phase Challenges: Case Series on Prolonged COVID-19 Infection in Immunocompromised Individuals

Prevalence of persistent SARS-CoV-2 in a large community surveillance study

Intra-host evolution during SARS-CoV-2 prolonged infection

Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment

Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants

Immune System Deficiencies Do Not Alter SARS-CoV-2 Evolutionary Rate but Favour the Emergence of Mutations by Extending Viral Persistence

Persistent SARS-CoV-2-positive over 4 months in a COVID-19 patient with CHB

SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency